Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13721332 | 0.92 | EGFR (0.50) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13720804 | 0.90 | EGFR (0.50) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13720284 | 0.90 | EGFR (0.50) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13720446 | 0.89 | KDM4E (0.45) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13720857 | 0.88 | KDM4E (0.43) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13858680 | 0.88 | KDM4E (0.45) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13720642 | 0.87 | ABCB1 (0.48) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL16155987 | 0.87 | PRMT1 (0.46) | KDM4EHPGDMEN1KMT2ACA12 | |
| SCHEMBL13720252 | 0.83 | KDM4E (0.41) | KDM4EHPGDMEN1KMT2AEGFR | |
| SCHEMBL13720767 | 0.82 | MAPK8 (0.42) | KDM4EHPGDMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | claimed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | claimed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | claimed |
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | KDM4E 751/4885HPGD 1562/4885MEN1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.